Cicabio Arnica+

• Anti-inflammatory and anti-swelling action
• Quickly reduces feeling of discomfort (ANTALGICINETM)
• Hydration power (+61%) *(1)
• Anti-bruising action, by preventing and resorbing the size of haematomas (2)

Good tolerance (3) - Creamy texture -non-comedogenic (4) - Quick and easy application (4) – Unfragranced(4)

Clinically tested on healthy volunteers, patients with sensitive skin or dry to moderately hydrated.

 * p< 0.05, Student-test, after 8 hours      

** p≤0.001, Wilcoxon -test, after 24 hours

(1) Evaluation of cutation hydration power, double-blind trial of Cicabio Arnica+ - 10 volunteers (aged 36 – 58 years old) with dry or moderately hydrated skin on the forearms with only one application. France
(2)Evaluation of the efficacy of Cicabio Arnica+ on an ex vivo haematoma model after 2 hours.
(3)Evaluation local skin tolerance with Cicabio Arnica+ - 21 volunteers (aged 30-66 years old with sensitive skin with only one application. France
(4)Evaluation of the skin local tolerance and the non-comedogenicity of Cicabio Arnica+ - 21 volunteers (aged 30 – 66 years old) with sensitive skin under normal condition. France. 2010

> CLINICAL RESULTS
Cicabio Arnica+ increased the level of skin hydration by 83%* over a 2-hour period and this action persisted at 8 hours (+61%)*(1).

ACTION ON BRUISES, OEDEMAS
The application of Cicabio Arnica + (2 mg/cm2), after the appearance of bruises leads to a significant reduction in the size of bruises (-40%) ** (2) compared to the control.
When applied before and after the appearance of bruises, the size of bruises is even more reduced (-65%) ** (2) compared to the control and statistically different from the group where it is used only after the bruises appear*.
Cicabio Arnica + can be used as a preventive and/or curative treatment.
The anti-inflammatory properties of Arnica montana have been demonstrated in vitro through the action of sesquiterpene lactones which inhibits the production of enzymes involved in the inflammatory cascade of the prostaglandins (key pro-inflammatory mediators) & reduces the recruitment of inflammatory cells.
AntalgicineTM, a synthetic biomimetic lipopeptide is an acetylated form of a peptide naturally present in the body: Kyotorphine, which interferes with the perception of pain. Kyotorphine has its own cellular receptors which activate an incoming calcium flow (IP3 gate) and cause a release of Met-enkephalin, thus inhibiting pain. In addition, in vitro studies on keratynocytes have shown that the addition of Antalgicine stimulates the synthesis of POMC, a precursor of endorphins and enkephalins.

TOLERANCE
Cicabio Arnica+ was evaluated as very well-tolerated after clinical examinations by a dermatologist after 28 days of using. (3)
 * p< 0.05, Student-test, after 8 hours      

** p≤0.001, Wilcoxon -test, after 24 hours

> PATIENTS FEEDBACKS
More than 70 % of the patients thought that after use, the skin is suppler and manifestation of discomfort and nagging pain were reduced. (4)
76% of patients thought that Cicabio Arnica+ was easy to apply and to spreads out (4)
The product leaves skin soft after use for 80% of the patients. (4)

(1)Evaluation of cutation hydration power trial of Cicabio Arnica+, double-blind trial - 10 volunteers (aged 36 – 58 years old) with dry or moderately hydrated skin on the forearms with only one application. France
(2)Evaluation of the efficacy of Cicabio Arnica+ on an ex vivo haematoma model after 2 hours.
(3)Evaluation local skin tolerance with Cicabio Arnica+ - 21 volunteers (aged 30-66 years old) with sensitive skin with only one application. France
(4)Evaluation of the skin local tolerance and the non-comedogenicity of Cicabio Arnica+ - 21 volunteers (aged 30 – 66 years old) with sensitive skin under normal condition. France 2010